GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bright Minds Biosciences Inc (XCNQ:DRUG) » Definitions » Retained Earnings

Bright Minds Biosciences (XCNQ:DRUG) Retained Earnings : C$-33.23 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Bright Minds Biosciences Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Bright Minds Biosciences's retained earnings for the quarter that ended in Dec. 2023 was C$-33.23 Mil.

Bright Minds Biosciences's quarterly retained earnings declined from Jun. 2023 (C$-30.02 Mil) to Sep. 2023 (C$-31.55 Mil) and declined from Sep. 2023 (C$-31.55 Mil) to Dec. 2023 (C$-33.23 Mil).

Bright Minds Biosciences's annual retained earnings declined from Sep. 2021 (C$-9.21 Mil) to Sep. 2022 (C$-24.18 Mil) and declined from Sep. 2022 (C$-24.18 Mil) to Sep. 2023 (C$-31.55 Mil).


Bright Minds Biosciences Retained Earnings Historical Data

The historical data trend for Bright Minds Biosciences's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bright Minds Biosciences Retained Earnings Chart

Bright Minds Biosciences Annual Data
Trend Sep20 Sep21 Sep22 Sep23
Retained Earnings
-0.56 -9.21 -24.18 -31.55

Bright Minds Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -26.51 -28.56 -30.02 -31.55 -33.23

Bright Minds Biosciences Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Bright Minds Biosciences  (XCNQ:DRUG) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Bright Minds Biosciences (XCNQ:DRUG) Business Description

Traded in Other Exchanges
Address
19 Vestry Street, New York, NY, USA, 10013
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Executives
Jeremy Fryzuk Director